Evidence map›Paper›PMID 40611414›Full record

ReviewCurrent cancer drug targets2026

Nucleolin as a Crucial Player in Head and Neck Cancer: Diagnostic and Therapeutic Perspectives.

Keerthivasu Ramasamy, Raksa Arun, Saif Feroz Khan, Sharon Prince, ArulJothi Kandasamy Nagarajan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Keerthivasu RamasamyDepartment of Genetic Engineering, College of Engineering and Technology, SRM Institute of Science and Technology, Potheri, Kattankulathur, Chengalpattu Dt, Chennnai, Tamilnadu, 603203, India.
Raksa ArunDepartment of Genetic Engineering, College of Engineering and Technology, SRM Institute of Science and Technology, Potheri, Kattankulathur, Chengalpattu Dt, Chennnai, Tamilnadu, 603203, India.
Saif Feroz KhanDepartment of Human Biology, Faculty of Health Sciences, Division of Cell Biology, University of Cape Town, Observatory, 7925, Cape Town, South Africa.
Sharon PrinceDepartment of Human Biology, Faculty of Health Sciences, Division of Cell Biology, University of Cape Town, Observatory, 7925, Cape Town, South Africa.
ArulJothi Kandasamy NagarajanDepartment of Genetic Engineering, College of Engineering and Technology, SRM Institute of Science and Technology, Potheri, Kattankulathur, Chengalpattu Dt, Chennnai, Tamilnadu, 603203, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and Neck Cancer (HNC) encompasses a diverse group of malignancies arising in the oral cavity, pharynx, larynx, and related structures. It represents a significant global health bur- den due to its high incidence, aggressive progression, and strong associations with environmental and viral risk factors like tobacco use and HPV infection. HNC, particularly squamous cell carcinoma, ranks as the seventh most common cancer worldwide. Despite the established role of these risk factors, the molecular mechanisms driving disease progression remain underexplored, especially in the context of specific biomarkers like Nucleolin (NCL). Nucleolin, a multifunctional protein, is pivotal in cancer progression, regulating cell proliferation, angiogenesis, and apoptosis. Data from The Cancer Genome Atlas (TCGA) reveal significant overexpression of NCL in HNC, particularly in advanced stages, correlating with poor prognosis and reduced patient survival. These findings highlight its potential as a diagnostic and therapeutic target. This review provides a fresh perspective on the underexplored potential of NCL as a therapeutic target in HPV-induced HNC and oral cancer. Emerging approaches, such as the AS1411 aptamer and F3 peptide, offer promising avenues for targeting NCL, paving the way for more effective, personalized cancer therapies.

Indexed as

Head and Neck NeoplasmsPhosphoproteinsRNA-Binding ProteinsAnimalsBiomarkers, TumorHuman Papillomavirus VirusesHumansMolecular Targeted TherapyNucleolinPrognosisBiomarkers, TumorNucleolinPhosphoproteinsRNA-Binding Proteinshead and neck cancerHPVNucleolintargeted therapyTCGA

Identifiers

PMID40611414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.